QIAGEN to return nearly $300 billion to shareholders through synthetic share buyback via Investing.com

• The return of capital will be made through the purchase of synthetic assets “combines a quick cash return to shareholders with a different stock dividend that improves EPS.

• A return of up to $300 million in “shareholder equity” will be completed by the end of January 2025.

• It builds on nearly $300 million returned to shareholders in early 2024 as part of a commitment to return at least $1 billion by the end of 2028.

VENLO, Netherlands–(BUSINESS WIRE)–QIAGEN NV (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a new plan to return approximately $300 million (approximately EUR 281 million) to shareholders dividends combine direct cash returns with stock dividends.

The new deal comes after QIAGEN returned about $300 million to shareholders in early 2024 through a repurchase. Together, these two programs represent a $600 million commitment to return at least $1 billion to shareholders by the end of 2028 (excluding M&A opportunities).

QIAGEN decided to implement the maximum value of $300 million of the mission given at the Annual General Meeting in June 2024, where the shareholders gave almost unanimous approval for the related decisions.

This method is designed to return money to shareholders in a faster and more efficient way than through the traditional open market repurchase program. It will also improve earnings per share (EPS) through a reduction in outstanding dividends.

QIAGEN has a proven track record of delivering on our commitments from our diverse portfolio, and this includes using our health balance sheet to improve our business while increasing returns to shareholders, said Thierry Bernard, CEO of QIAGEN. This new acquisition marks an important step in creating value for our shareholders and other stakeholders as we fulfill our 2028 ambitions to deliver solid profit growth.

Roland Sackers, QIAGEN’s Chief Financial Officer, said: Our proprietary procurement structure is a well-known and proven quality improvement method used by many Dutch companies. QIAGEN will continue to have a solid investment position after completing this acquisition in early 2025. We are exploring various targeted M&A opportunities and organic growth investments that will help us achieve our commitments ours for solid profit growth.

This type of share purchase involves three steps:

(1)		The par value of QIAGEN ordinary shares (EUR 0.01 per share) will be increased by a transfer from the Share Premium Reserve (included in Paid-in Capital on the Company’s balance sheet) to allow the return of capital to shareholders.
(2)		A reverse stock split will combine shares.
(3)		The par price will be reduced back to the original level of EUR 0.01 per share and the capital return will be paid directly to the shareholders (as of the record date, and where necessary after conversion to US dollars).

The sale of artificial goods will take effect on January 28, 2025, and will be settled according to market consensus in the following days. More information about this process will be announced before the implementation.

About QIAGEN

QIAGEN NV, a proprietary company based in the Netherlands, is the world’s leading provider of Sample to Insight solutions that enable customers to obtain valuable molecular information from biological samples. Our sampling technologies isolate and process DNA, RNA and proteins from blood, tissues and other materials. Analytical technology makes these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases translate data into accurate, actionable information. Automated solutions bring these together in a seamless and cost-effective manner. QIAGEN provides solutions to more than 500,000 customers worldwide in Molecular Diagnostics (human health care) and Life Sciences (academia, pharma R&D and industrial applications, especially forensics). As of September 30, 2024, QIAGEN employs more than 5,800 people in more than 35 locations worldwide. More information can be found at https://www.qiagen.com.

Forward-Looking Statement

Certain statements in this press release may be considered forward-looking statements within the meaning of Section 27A of the US Securities Act of 1933, as amended, and Section 21E of the US Securities Exchange Act of 1934 , as amended. To the extent any of the statements contained herein relate to QIAGEN products, including products used in response to the COVID-19 outbreak, the timing of launch and development, marketing and/or regulatory approval , financial and operational outlook, growth and expansion. , transactions, markets, strategy or results of operations, including without limitation, its expected adjusted sales and adjusted earnings results, are forward-looking, such statements are based. about current expectations and assumptions that involve many uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks related to growth management and international operations (including the effects of currency fluctuations, regulatory processes and the reliability of goods), differences in performance results and distributions between customer groups, business development. of markets for our products to customers in academia, pharma, applied testing and molecular diagnostics; changing relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technology; fluctuations in demand for QIAGEN’s products (including fluctuations due to general economic conditions, the level and timing of customer finances, rates and other factors); our ability to obtain regulatory approval for our products; difficulties in successfully integrating QIAGEN’s products into joint solutions and developing such products; QIAGEN’s ability to identify and develop new products and to differentiate and protect our products from competitors’ products; market acceptance of QIAGEN’s new products and technology integration with acquired businesses; actions of governments, global or regional economic developments, weather or transportation delays, natural disasters, political or public health disasters, including the extent and duration of the COVID-19 pandemic and its impact on demand for our products and other areas of our business. , or other force majeure events; as well as the possibility that anticipated benefits related to current or pending acquisitions may not materialize as anticipated; and other factors discussed under the heading Risk Factors contained in Item 3 of our most recent Annual Report on Form 20-F. For more information, please refer to the discussion in the reports that QIAGEN has filed with, or filed with, the US Securities and Exchange Commission.

Source: QIAGEN NV
Category: Finance

Check out the source version at businesswire.com: https://www.businesswire.com/news/home/20250112318507/en/

QIAGEN:

IInvestor Relations
John Gilardi +49 2103 29 11711
Domenica Martorana +49 2103 29 11244
email: ir@QIAGEN.com

Public relations
Thomas Theuringer +49 2103 29 11826
Lisa Specht +49 2103 29 14181
email: pr@QIAGEN.com

Source: QIAGEN NV